Stocks Health care NBP
NASDAQ · Health careNovaBridge Biosciences (NBP)
It posted a net loss of $46.3M. In fiscal 2025 capital spending exceeded operating cash flow by $20.6M. At December 31, 2025 it held $210.6M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer, amended) (20-F/A) filed on June 16, 2026.
Key facts about NovaBridge Biosciences
- Net worth
- NovaBridge Biosciences has a market value (market cap) of $104.9M at the latest share price, and shareholders' equity of $230.9M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2023 revenue was $632K, with a net loss of $207.7M.
- Cash flow
- In fiscal 2025 operations used $20.6M of cash.
- Latest report
- The latest periodic report (annual report (foreign issuer, amended), 20-F/A) was filed with the SEC on June 16, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR
What NovaBridge Biosciences does
NovaBridge Biosciences is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker NBP.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$46.3M | -$0.21 | -$20.6M |
| 2024 | n/a | -$22.2M | -$0.12 | -$52.7M |
| 2023 | $632K | -$207.7M | -$1.09 | -$184M |
| 2022 | -$1.6M | -$371.1M | -$1.96 | -$162M |
| 2021 | $13.8M | -$365.9M | -$2.09 | -$157.4M |
| 2020 | $236.4M | $72.2M | $0.46 | $65.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What NovaBridge Biosciences has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Activist stake changed SCHEDULE 13D/A
- October 28, 2026
- October 26, 2026
- October 23, 2026
- October 13, 2026
- September 8, 2026
- September 8, 2026
- August 20, 2026
- August 20, 2026
- August 17, 2026
Insider trades
What the people running NovaBridge Biosciences did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $88.3K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 15, 2026 | Woo Ian YingDirector | Exercised options | 13,271 | - |
| September 18, 2026 | Dennis Phillip AndrewChief Medical Officer | Sold | 8,209 | $5.8K |
| September 17, 2026 | Dennis Phillip AndrewChief Medical Officer | Exercised options | 23,695 | - |
| September 9, 2026 | Cao Sean WuxiongChief Bus. Development Officer | Sold | 107,978 | $79.9K |
| September 3, 2026 | Cao Sean WuxiongChief Bus. Development Officer | Exercised options | 235,136 | - |
| September 3, 2026 | Cao Sean WuxiongChief Bus. Development Officer | Exercised options | 104,236 | - |
| August 31, 2026 | Xu Cong ClaireEVP, Clinical Development | Sold | 3,282 | $2.6K |
| August 30, 2026 | Xu Cong ClaireEVP, Clinical Development | Exercised options | 9,382 | - |
Who owns NBP
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Everest Medicines Limited13D, may seek influence | 16.1% | August 5, 2025 |
| Wei Fu13D, may seek influence with 11 related filers | 11.5% | February 3, 2026 |
Largest institutional holders
Insiders
6 insiders reported holding 1,004,584 shares in total, about $913K at the last price.
| Holder | Shares |
|---|---|
| Xu Cong ClaireEVP, Clinical Development | 304,201 |
| Cao Sean WuxiongChief Bus. Development Officer | 266,467 |
| Hagler Mark ArnoldSee Remarks | 230,000 |
| Dennis Phillip AndrewChief Medical Officer | 173,427 |
| Lenz Robert A.Director | 17,218 |
| Woo Ian YingDirector | 13,271 |
Questions about NBP
What does NovaBridge Biosciences do?
NovaBridge Biosciences is a company in the Health care sector, listed on NASDAQ as NBP. Its shares trade on NASDAQ under the ticker NBP.
What is NovaBridge Biosciences's net worth?
NovaBridge Biosciences has a market value (market cap) of $104.9M at the latest share price, and shareholders' equity of $230.9M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is NovaBridge Biosciences profitable?
No. In fiscal 2025 it reported a net loss of $46.3M.
When did NovaBridge Biosciences last report?
Its most recent periodic report is the annual report (foreign issuer, amended) (20-F/A) filed on June 16, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the activist stake changed from November 5, 2026.
Similar companies
Compare NBP with
Follow NBP
Get an email when NovaBridge Biosciences files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values NovaBridge Biosciences tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.